Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment

Chun Jen Liu, I. Shyan Sheen, Chi Yi Chen, Wan Long Chuang, Horng Yuan Wang, Kuo Chih Tseng, Ting Tsung Chang, Jenny Yang, Benedetta Massetto, Vithika Suri, Gregory Camus, Deyuan Jiang, Fangqiu Zhang, Anuj Gaggar, Tsung Hui Hu, Yu Chun Hsu, Gin Ho Lo, Chi Jen Chu, Jyh Jou Chen, Cheng Yuan PengRong Nan Chien, Pei Jer Chen

研究成果: Article同行評審

6 引文 斯高帕斯(Scopus)

摘要

Background: For patients coinfected with hepatitis C virus (HCV) and hepatitis B virus (HBV), HCV treatment with direct-acting antivirals can lead to HBV reactivation. We evaluated HBV reactivation during ledipasvir/sofosbuvir treatment and 108-week follow-up. Methods: In Taiwan, 111 patients with HCV genotype 1 or 2 and HBV received ledipasvir/sofosbuvir (90mg/400mg) once daily for 12 weeks. HBV virologic reactivation was defined as postbaseline increase in HBV DNA from either less than the lower limit of quantification (LLOQ, 20 IU/mL) to equal to or more than LLOQ or equal to or more than LLOQ to >1 log10 IU/mL. HBV clinical reactivation was HBV virologic reactivation with alanine aminotransferase (ALT) >2× upper limit of normal. Factors associated with development of HBV virologic or clinical reactivation were evaluated with logistic regression analysis. Results: All patients (100%, 111/111) maintained HCV suppression through 108 weeks after treatment. HBV virologic reactivation occurred in 73% of patients (81/111). Clinical reactivation occurred in 9% (10/111). The majority of HBV virologic reactivations (86%, 70/81) occurred by follow-up week 12, whereas clinical reactivation was generally more delayed. Eight (7%, 8/111) initiated HBV therapy. In regression analyses, baseline HBV DNA and hepatitis B surface antigen (HBsAg) levels were associated with HBV virologic reactivation and baseline ALT and HBV DNA, and HBsAg levels were associated with HBV clinical reactivation. Conclusion: Among HCV/HBV coinfected patients treated with direct-acting antivirals for HCV, HBV virologic reactivation occurred in a majority of patients during treatment and follow-up. In most patients, HBV virologic reactivation was asymptomatic; only a small proportion initiated HBV treatment. Notably, clinical reactivation may still occur >3 months after end of therapy. Clinical Trials Registration: NCT02613871.

原文English
頁(從 - 到)453-459
頁數7
期刊Clinical Infectious Diseases
75
發行號3
DOIs
出版狀態Published - 2022 8月 1

All Science Journal Classification (ASJC) codes

  • 微生物學(醫學)
  • 傳染性疾病

指紋

深入研究「Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment」主題。共同形成了獨特的指紋。

引用此